Document ID: chunk:federal_register_of_legislation:F2024C01228:front:0:p5
Version: federal_register_of_legislation:F2024C01228
Segment Type: other
Provision Reference: 
Character Range: 10301–12792

<15mL/min, relapsing or persistent nephrotic syndrome; or
 (E) proven or presumptive cerebrospinal fluid (CSF) leak; or
 (F) cochlear implants; or
 (G) intracranial shunts; or
 (H)  previous episode of invasive pneumococcal disease (IPD); or
 (I) born less than 28 weeks gestation; or
 (J) trisomy 21; or
 (K) chronic heart disease including cyanotic heart disease and heart failure;
 (ii) who is aged at least 5 years and has been newly diagnosed with one or more of the medical risk conditions contained in subparagraphs (a)(i)(A)‑(H);
 (iii) who is an Aboriginal and/or Torres Strait Islander aged at least 4 years but less than 6 years and who lives in Queensland, Western Australia, South Australia or the Northern Territory;
 (iv) who is an Aboriginal and/or Torres Strait Islander aged at least 50 years and who has not received a dose of the vaccine under (ii);
 (b) a second dose of the vaccine may be provided to a person mentioned in paragraph (a) at least 5 years after the first dose was provided to the person under paragraph (a).
 (3) For item 113 of Schedule 1, a designated vaccine mentioned in that item may be provided to a person:
 (a) who is at least 15 years; and
 (b) who is one of the following:
 (i) an abattoir worker;
 (ii) a sheep shearer;
 (iii) a sheep, dairy or beef cattle farmer;
 (iv) an employee of a sheep, dairy or beef cattle farmer;
 (v) a member of the family of a sheep, dairy or beef cattle farmer who works on the sheep, dairy or beef cattle farm;
  (vi)   an employee of a tannery; and
 (c) who has had a Q‑Vax skin test and has received a negative result for that test; and
 (d) who has had a Coxiella burnetii antibody serum study and has received a negative result for that study.
 (4) For item 203 of Schedule 1, a designated vaccine mentioned in that item may be provided in the following circumstances:
 (a) a dose of the vaccine may be provided to a newborn infant as soon as practicable after birth but no later than 7 days after birth;
 (b) a first dose of the vaccine may be provided to a child who is at least 10 years but less than 14 years;
 (c) a second dose of the vaccine may be provided to a child mentioned in paragraph (b) 1 month after the first dose was provided to the child under paragraph (b);
 (d) a third dose of the vaccine may be provided to a child mentioned in paragraph (b) 5 months after the second dose was provided to the child under paragraph (c).
 (5) For items 205, 208, 209 and 210 of Schedule 1, a designated